|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The most commonly detected mutation was the BRAF c.1799 T > A in all non-classical PTC cases.
|
31758407 |
2020 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
The BRAF-like profile had a significantly better outcome compared with RAS-like and NoBRaL (11.8, 6.2 and 5.5 months, respectively), HR: 0.31 (95% CI 0.17-0-60) p<0.001) and HR:0.36 (95% CI 0.21-0.63, p<0.001) and maintained significance as an independent prognostic factor for overall survival in the multivariate analysis for papillary thyroid cancers.
|
31540966 |
2020 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure.
|
31135058 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Vemurafenib is a selective BRAF inhibitor (BRAFi) that has shown promising activity in BRAF<sup>V600E</sup>-positive papillary thyroid cancer (PTC).
|
30869573 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
|
30819583 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to estimate the diagnostic value of BRAF V600E mutation status combined with cytomorphological features for diagnosis of papillary thyroid cancer (PTC) in cytologically indeterminate thyroid nodules.
|
29566402 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
|
30999281 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Mutations of BRAF oncogene are considered to contribute in the invasiveness and poor clinicopathologic features of papillary thyroid cancer (PTC).
|
30890403 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
To the best of our knowledge, this case is the first case to report two different BRAF mutations in tissues of a Langerhans cell histiocytosis and a papillary thyroid carcinoma co-existing in the thyroid gland.
|
30795755 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of BRAF V600E and TERT coexistence in PTC was 2.1%.
|
31300059 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Central lymph node metastasis (CLNM) was independent of the BRAF mutation status and accounted for 34.2% of the patients with PTC.
|
31441082 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
In 175 cytologically indeterminate thyroid nodules, BRAF mutation identified 88% of PTC.
|
31305422 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.
|
30896061 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
ATC with PTC components is typically characterised by a BRAF mutation with a late mutation event, whereas PDTC with PTC components is more closely correlated with RET fusion.
|
31230400 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 15 patients with N0 PTC by ultrasound and BRAF mutation on preoperative biopsy treated with total thyroidectomy (TT) or TT + prophylactic central neck dissection (PCND) alone or with SNB.
|
30688735 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas.
|
31810221 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, RET/PTC rearrangements and BRAF mutations were associated with the different clinical and histopathological features in pediatric PTC.
|
31085772 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Wild-type BRAF and RAS in NIFTP was significantly higher than I-EFVPTC.
|
31276506 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Fine needle aspiration confirmed papillary thyroid carcinoma with BRAF mutation.
|
31439567 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC with BRAF mutation presents a histology of conventional PTC, and follows an aggressive clinical course.
|
30788603 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
To investigate the mutant status of BRAF gene, and analyze its relationship to epidemiological risk factors and clinical outcomes among patients with papillary thyroid cancer (PTC) in the largest, single-institution Chinese cohort to date.
|
31252408 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Targeted next-generation sequencing was performed for two cases of BRAF-wild type PTC with confirmation of the results by Sanger sequencing.
|
30466862 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, miR-22 serum levels were increased in patients with PTC and the B-Raf proto-oncogene, serine/threonine kinase V600E mutation.
|
30867770 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We aimed to clarify the IHC expression of p53, Ecadherin and BRAF as potential markers of RNR in PTC.
|
31031216 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
A total thyroidectomy with bilateral lymph node dissection was performed and the microscopic examination revealed a 2-cm PTC with BRAF mutation and HL (mixed cellularity) in the bilateral lymph nodes.
|
30653166 |
2019 |